Bergen, Norway, 18 May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference:
7th Annual Immuno-Oncology Innovation Forum (SACHS), May 18, 2021
Live presentation at 13.10 PM EDT zone
The presentation will be made available on the Company website: www.bergenbio.com/investors/presentations/
